Polomar Health Services, Inc. 10-K — AI Bull & Bear Analysis

The 10-K filing reveals a company in a race against time, attempting to bridge the gap between a fragile financial state and a high-potential product pipeline. Polomar has successfully shifted its business model toward the lucrative GLP-1 market and established key wholesale partnerships, but these wins are overshadowed by a 'going concern' warning from auditors. The tension lies in whether the company can execute the Altanine merger and secure a $25 million equity credit line before its remaining cash is exhausted. Ultimately, Polomar is a binary bet on execution. The success of the pre-filled pen system and the ability to scale pharmacy licenses across 28+ states could lead to explosive growth. However, the current reliance on related-party debt and the absence of D&O insurance highlight a level of corporate fragility that may deter all but the most aggressive investors. The coming quarters will determine if Polomar becomes a disruptive force in digital health or a cautionary tale of over-leverage and execution failure.